A collaboration involving a Swedish business consortium and NVIDIA is set to revolutionize AI infrastructure in Sweden. The project, aimed at advancing the nation's key industries into the AI era, includes major companies such as AstraZeneca (AZN, Financial), Ericsson, Saab, and SEB, alongside Wallenberg Investments. They plan to establish an advanced computing system, featuring NVIDIA's accelerated technology, which will be managed by a newly formed joint venture to ensure secure and exclusive compute access for its partners.
The first phase of this initiative will introduce two NVIDIA DGX SuperPODs integrated with the state-of-the-art Grace Blackwell GB300 systems. Once operational, this will become Sweden’s largest enterprise AI supercomputer, playing a crucial role in executing high-intensity AI workloads. It will significantly enhance processes such as the training of specialized AI models and executing large-scale AI inference tasks, including intricate reasoning operations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for AstraZeneca PLC (AZN, Financial) is $100.36 with a high estimate of $233.46 and a low estimate of $67.00. The average target implies an upside of 42.53% from the current price of $70.41. More detailed estimate data can be found on the AstraZeneca PLC (AZN) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, AstraZeneca PLC's (AZN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AstraZeneca PLC (AZN, Financial) in one year is $90.30, suggesting a upside of 28.25% from the current price of $70.41. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AstraZeneca PLC (AZN) Summary page.
AZN Key Business Developments
Release Date: April 29, 2025
- Total Revenue Growth: 10% in Q1 2025.
- Core Operating Profit Growth: 12% increase.
- Core EPS Growth: 21% increase, benefiting from a lower tax rate.
- Gross Margin: 84% in Q1 2025.
- Core R&D Costs: Increased by 16%, representing 23% of total revenue.
- Core SG&A Costs: Increased by 4%.
- Core Operating Profit Margin: 35%.
- Core Tax Rate: 16% in Q1 2025.
- Cash Inflows from Operating Activities: $3.7 billion.
- CapEx: Approximately $500 million, expected to increase by 50% this year.
- Net Debt: Increased by $1.5 billion to $26.1 billion.
- Oncology Revenue Growth: 13% to $5.6 billion in Q1 2025.
- Biopharmaceuticals Revenue Growth: 12% to $5.6 billion in Q1 2025.
- Rare Disease Revenue: $2 billion, stable year-on-year.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- AstraZeneca PLC (AZN, Financial) reported a strong start to 2025 with a 10% increase in total revenue, driven by demand for innovative medicines.
- Core operating profit increased by 12% and core EPS rose by 21%, reflecting effective cost management and operating leverage.
- The company secured 13 approvals in key regions, showcasing the global impact of its diverse portfolio.
- AstraZeneca PLC (AZN) announced five positive Phase III results, including two NMEs, indicating strong pipeline delivery.
- The company is on track to deliver at least 20 NMEs by 2030, with nine novel medicines already approved.
Negative Points
- AstraZeneca PLC (AZN) faces anticipated headwinds, including Medicare Part D redesign in the US, which could impact revenue.
- The company expects a decline in total revenue gross margin by 60 to 70 basis points in 2025 due to various factors, including SOLIRIS biosimilar competition.
- There is a potential impact from VBP inclusion in China, which could affect pricing and revenue for certain products.
- AstraZeneca PLC (AZN) anticipates a lower gross margin in the second half of the year due to seasonal patterns and other factors.
- The company is facing increased competition in the rare disease segment, which could impact growth in this area.
